OPKO Health Inc (OQ:OPK)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
 
See Regulatory Filings on SEC
Company Contact
Address: 4400 Biscayne Blvd.
MIAMI FL 33137
Tel: 1-310-6917100
Website: https://www.opko.com
IR: See website
<
Key People
Phillip Frost
Chairman of the Board, Chief Executive Officer
Elias A. Zerhouni
President, Vice Chairman of the Board
Jane H. Hsiao
Vice Chairman of the Board, Chief Technical Officer
Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Charles W. Bishop
Chief Executive Officer of OPKO Renal
Tony F. Cruz
Chief Executive Officer, Transition Therapeutics, Inc
Steven D. Rubin
Executive Vice President - Administration, Director
Gary J. Nabel
Chief Innovation Officer, Director
 
Business Overview
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
Financial Overview
For the six months ended 30 June 2024, OPKO Health Inc revenues decreased 29% to $355.9M. Net loss increased from $37.9M to $92.1M. Revenues reflect Pharmaceutical segment decrease of 78% to $52.8M, Diagnostics segment decrease of 1% to $256.3M, Ireland segment decrease of 83% to $19.1M, United States segment decrease of 14% to $277.8M, Israel segment decrease of 90% to $601K.
Employees: 3,930 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,179M as of Sep 30, 2024
Annual revenue (TTM): $716.37M as of Sep 30, 2024
EBITDA (TTM): -$164.27M as of Sep 30, 2024
Net annual income (TTM): -$243.10M as of Sep 30, 2024
Free cash flow (TTM): -$86.07M as of Sep 30, 2024
Net Debt Last Fiscal Year: $167.63M as of Sep 30, 2024
Shares outstanding: 697,376,055 as of Aug 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.